
Search
Filter Results
Displaying 101–110 of 609 for “retinal diseases”
-
Sep 16, 2024
Foundation Fighting Blindness Hosts Chicago Night for Sight Event
The October 5th event will raise awareness and fund research driving treatments and cures for blinding diseases and macular degeneration.
-
Why Genetic Testing is Important
An Overview of Genetic Testing for Inherited Retinal Degenerative Diseases
-
The My Retina Tracker Registry is a research database of people and families affected by inherited retinal degenerative diseases.
-
Apr 25, 2018
ARVO 2018: World's Largest Show and Tell for Innovations in Eye Research
More than 11,000 eye researchers from around the world — including five intrepid members from FFB’s science team — will gather to participate in what is essentially a massive “show and tell” of the latest scientific advancements.
-
Dec 20, 2017
History Is Made: FDA Approves Spark's Vision-Restoring Gene Therapy
Known as LUXTURNA™ (voretigene neparvovec), the gene therapy restored vision in a clinical trial for people between the ages of 4 and 44 with Leber congenital amaurosis (LCA) caused by mutations in the gene RPE65.
-
Oct 20, 2020
RP Treatment Derived from Induced Pluripotent Stem Cells Advances into Clinical Trial
The stem cells were derived from mature blood cells and coaxed to become photoreceptors
-
Aug 15, 2018
FFB Provides Four Career Development Awards to Up-and-Coming Clinical Researchers
Each recipient will receive a total of $375,000 over five years to help build an independent research program in addition to their clinical practices.
-
Nov 5, 2013
Is Acupuncture a Beneficial Treatment for Retinitis Pigmentosa?
Acupuncture definitely has potential benefits, and the breadth of those is being aggressively explored.
-
Aug 3, 2020
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
May 5, 2021
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Gene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies